Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-19
2006-12-19
Kwon, Brian (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S254020, C514S252190
Reexamination Certificate
active
07151103
ABSTRACT:
The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.
REFERENCES:
patent: 3406178 (1968-10-01), Crocker et al.
patent: 3472854 (1969-10-01), Archer
patent: 4200641 (1980-04-01), Vandenberk et al.
patent: 4737500 (1988-04-01), Sorg
patent: 4797399 (1989-01-01), Ueda et al.
patent: 4859692 (1989-08-01), Bernstein et al.
patent: 4886803 (1989-12-01), Sueda et al.
patent: 4940793 (1990-07-01), Botre et al.
patent: 4954503 (1990-09-01), Strupczewski et al.
patent: 5036088 (1991-07-01), Kitaura et al.
patent: 5576318 (1996-11-01), Bietti et al.
patent: 5883094 (1999-03-01), Fliri et al.
patent: 6281218 (2001-08-01), Cereda et al.
patent: 6284757 (2001-09-01), Sanner
patent: 6521623 (2003-02-01), Cereda et al.
patent: 6586435 (2003-07-01), Cereda et al.
patent: 2003/0060475 (2003-03-01), Borsini
patent: 2003/0083228 (2003-05-01), Carpino et al.
patent: 2003/0119850 (2003-06-01), Bombarda et al.
patent: 2004/0048877 (2004-03-01), Friedl et al.
patent: 2004/0180904 (2004-09-01), Beck
patent: 2004/0235861 (2004-11-01), Borsini
patent: 2005/0065158 (2005-03-01), Naylor et al.
patent: 2005/0159430 (2005-07-01), Bombarda et al.
patent: 2005/0239798 (2005-10-01), Pyke
patent: 2005/0245539 (2005-11-01), Mendla et al.
patent: 2006/0014757 (2006-01-01), Pyke
patent: 2006/0025420 (2006-02-01), Brauns et al.
patent: 0200322 (1986-11-01), None
patent: 0 526 434 (1993-02-01), None
patent: 0705832 (1996-04-01), None
patent: 0816356 (1998-01-01), None
patent: 0982030 (2000-03-01), None
patent: 1256343 (2002-11-01), None
patent: 2023594 (1980-01-01), None
patent: WO 95/034555 (1995-12-01), None
patent: WO 98/42344 (1998-10-01), None
patent: WO 200028993 (2000-05-01), None
patent: WO 01/21593 (2001-03-01), None
patent: WO 03/013539 (2003-02-01), None
patent: WO 03/014079 (2003-02-01), None
“Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety”, Podhorna et al., abstract, British Journal of Pharmacology, 2000, vol. 130, No. 4, pp. 739-746.
Rueter, L. E. et al; “Electrophysiological examination of the effects of sustained flibanserin administration on serotonin receptors in rat brain”; British J of Pharm, 1999, vol. 126, No. 3, pp. 627-638.
Cools, A. R. “Depression and Psychosis” Behavioural Pharmacology of 5-HT, pp. 153-155 (1989).
Geyer, M. “5-HT2 antagonists increase tactile startle habituation in an animal model of habituation deficit in schizophrenia” Behavioural Pharmacology of 5-HT, pp. 243-246 (1989).
Bevan et al. “5-HT and Sexual Behaviour” Behavioural Pharmacology of 5-HT, pp. 33-34, 87-88 (1989).
Archer, T. “5HT, Pain and Anxiety” Behavioural Pharmacology of 5-HT, p. 299-300 (1989).
Cloninger, C. R. “A Systematic Method for Clinical Description and Classification of Personality Variants” Arch. Gen. Psychiatry, vol. 44, pp. 573-588 (Jun. 1987).
Leonard, B. E. “Sub-types of serotonin receptors: biochemical changes and pharmacological consequences” International Clinical Psychopharmacology 7, 13-21 (1992).
Reikkinen et al. “The Effects of Increased Serotonergic and Decreased Cholinergic Activities on Spatial Navigation Performance in Rats” Pharmacology Biochemistry & Behavior, vol. 39, pp. 25-29 (1991).
Crook, T. and Lakin, M. “Effects of Ondansetron in Age-associated Memory Impairment” The role of ondansetron, a novel 5-HT3 antagonist, in the treatment of psychiatric disorders, 5th World Congress of Biochemical Psychiatry, pp. 21-23 (1991).
Darlington, C. “Flibanserin” Current Opinion in CPNS Investigational Drugs, 1999 1(4): 510-513.
Borsini et al. Behavioral Effects of Flibanserin (BIMT-17), Sep. 1999, Pharmacology, Biochemistry and Behavior, vol. 64, issue 1, see abstract.
Borsini, F. et al. “BIMT-17, a 5HT-2A receptor antagonist and 5HT-1A receptor full agonist in rat cerebral cortex” Naunyn-Schmiedeberg's Archives of Pharm., 352(3) 1995, pp. 276-282.
Giron, D. “Thermal analysis and calorimetric methods in the characterization of polymorphs and solvates” Thermochimica ACTA, Elsevier Science, 248, 1995, pp. 1-59.
Bernstein, J. et al. “Concomitant polymorphs” Angewandte Chemise, Int. Ed., 1999, pp. 3441-3461.
Borsini et al., Flibanserin, Drugs of the Future, 1998, 23(1):9-16.
Jean L. Fourcroy “Female Sexual Dysfunction: Potential for Pharmacotherapy” Drugs 2003, vol. 63, No. 14, pp. 1445-1457.
Steiner, M. “Recognition of Premenstrual Dysphoric Disorder and Its Treatment” The Lancet, vol. 356, No. 9236, Sep. 30, 2000, pp. 1126-1127.
Dimmock, P. et al. “Efficacy of Selective Serotonin-Reuptake Inhibitors in Premenstrual Syndrome: A Systematic Review” The Lancet, vol. 356, No. 9236, Sep. 30, 2000, pp. 1131-1136.
Greene, T. “Protective Groups in Organic Synthesis”, Havard University, pp. 10-17, 1981 (Wiley-Interscience Publication).
Chemical Abstract: Database Accession No. 98:16650-XP 002197885 Collino, F. et al.: Mannich bases of benzimidazoles, benzotriazoles and other analogous compounds, with pharmacological activity.
Chalmers et al., “Corticotrophin-releasing factor receptors: from molecular biology to drug design”, TiPS vol. 17, pp. 166-172, Apr. 1996.
Lyrer, “Neue Ansatze in der Akutbehandlung des zerebrovaskularen Insultes” Schweiz. Med. Wochenschr., vol. 124, #45, 2005-2012 1994.
Frampton et al., Pentoxifylline (Oxpentifylline) A Review of its Therapeutic Efficacy in the Management of Peripheral Vascular and Cerebrovascular Disorders; (Drug Evaluation) Drugs and Aging 7(6), pp. 480-503, 1995.
Damour et al. CA 118-124537e (1992).
Awouters et al. CA 88-98788 (1977).
Vaudenberk et al. CA 88-50920n (1977).
Invernizzi et al., “Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT1Areceptors”, British Journal of Pharmacology, vol. 139, pp. 1281-1288, Jun. 2003.
Borsini Franco
Evans Kenneth Robert
Boehringer Ingelheim Corp.
Boehringer Ingelheim Pharma KG
Kwon Brian
LandOfFree
Method of treating female hypoactive sexual desire disorder... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating female hypoactive sexual desire disorder..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating female hypoactive sexual desire disorder... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3715723